New Inhalation Anthrax Vaccine

by Medindia Content Team on  September 3, 2004 at 11:09 AM General Health News
RSS Email Print This Page Comment
Font : A-A+

New Inhalation Anthrax Vaccine
A new anthrax vaccine may offer a faster and easier way to protect the general population and soldiers at war in the event of a deadly bioterror attack. Scientists have developed a powdered form of the vaccine that could potentially be inhaled through the nose, thus eliminating needle injections.

The new formulation is based on an anthrax recombinant protective antigen (rPA), a genetically engineered protein. Researchers say the powdered formula is more stable than the injected liquid version and can withstand wider temperature extremes, in more extreme conditions without refrigeration.

The vaccine has not yet been tested in humans, but investigators say clinical trials could be possible within the next two to three years.In laboratory tests using rabbits exposed to a lethal dose of inhalation anthrax, nasal immunization with the powder resulted in an 83-percent to 100-percent survival rate. The results are similar to the protection offered by the injected formula.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Anthrax Bioterrorism Top 10 Vaccine Myths Debunked 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive